And whether you know...
In addition: anhydrous colloid silicon dioxide, microcrystallic cellulose, talc, croscarmellose sodium, krakhmalglikolit sodium (type A), magnesium stearate, a gipromelloz, titanium dioxide (E 171), polyethyleneglycol 6000, dye a decline yellow FCF (E 110).
Moveks the Asset is made in the form of tablets in a cover, on 30 or 60 pieces in bank.
Hondroprotektorny, antiinflammatory, regenerative, anesthetizing.
Pharmacodynamics and pharmacokinetics
Moveks the Asset is medicine with the picked-up combination of active ingredients which combined activity is directed to rendering hondroprotektorny, antiinflammatory, regenerative and analgeziruyushchy action, generally in relation to joint fabrics. Effects of drug slow down processes of degradation of bone and cartilaginous tissue, at injuries promote forming of a bone callosity and reconstruction of a cartilage, and also recovery of functionality of joints.
Substrate of forming of a joint cartilage – a glycosamine – stimulates regenerative mechanisms of recovery of cartilaginous tissue. Any, whether it be external or internal negative factors, (injuries, pathologies, age degenerative disturbances, frustration of a metabolism) reduce synthesis of a glycosamine and its content in connecting fabric that often becomes the reason of structural deformation of joints and to forming of a pain syndrome. Important fragments of a difficult cartilaginous matrix are glikozaminoglikana and proteoglycans, and the structure of endogenous cartilaginous glikozaminoglikan and includes a glycosamine which possesses hondroprotektorny qualities, promotes decrease in insufficiency of glikozaminoglikan in an organism and takes part in synthesis of hyaluronic acid and proteoglycans. Owing to the selective influence on tissue of cartilages, a glycosamine activates process of fixation of sulfur at the time of synthesis of chondroitinsulphuric acid, limits deposits in a bone tissue of calcium, favors to recovery of functionality of joints, and also decrease or full elimination of their morbidity. Also the glycosamine suppresses formation of the superoxidic anions and enzymes leading to cartilage tissue damage (a phospholipase, a collagenase), prevents destructive impact on chondrocytes of glucocorticoids and disturbance of processes of biosynthesis of the glikozaminoglikan which are shown at reception of NPVS.
In case of oral administration bioavailability of a glycosamine is equal to 25-26%. The highest level of a glycosamine at distribution in fabrics is defined in livers/kidneys and tissues of cartilages. About 90% of the drug which arrived inside are soaked up in a small bowel in the form of salt of a glycosamine and already from there, thanks to a portal blood-groove, comes to a liver. The most part of a glycosamine is exposed to a hepatic metabolism and breaks up to carbon dioxide, water and urea. About 30% of a dose long enough are in connecting fabric. Excretion is carried out with urine and in very small quantity with a stake.
High-molecular polysaccharide – chondroitin – takes part in forming of cartilaginous tissue of joints, stimulates its regeneration, supports a viscous consistence of synovial fluid, and also oppresses enzymatic activity of hyaluronidase and elastase, destructively influencing a joint cartilage. Positively influences processes of a phosphorus-calcium exchange in cartilage tissues, slows down a pathological caries and slows down development of osteoporosis. Podavlyayushche influences inflammatory process at early stages of its forming, thereby slowing down degenerative metamorphoses of cartilaginous tissue. Shows some analgetic activity, improves functionality of joints and reduces need for use of NPVS. Counteracts consolidation of connecting fabric, normalizes release of joint liquid and "greases" the adjoining joint surfaces.
At one-time oral administration, plasma Cmax of chondroitin is reached after 3-4 hours, and its Cmax in synovial fluid, exceeding plasma, after 4-5 hours. Bioavailability is at the level of 13-15%. For 24 hours there is a full removal of chondroitin to urine.
Drug of NPVS group – diclofenac – is characterized by quite fast analgeziruyushchy, antipyretic and antiinflammatory efficiency that is important at therapy of the pains of acuity which are observed in the conditions of an inflammation. Activity of diclofenac is shown thanks to its ability to blocking of production of enzyme cyclooxygenase owing to what there is a suppression of synthesis of prostaglandins playing the main role in emergence of an inflammation, fever and pain. Diclofenac mainly oppresses a phase of exudation and somewhat a proliferation phase, thereby reducing synthesis of collagen and the sklerozirovaniye of fabrics depending on it. Reduction of a pain syndrome is observed as at rest, and at the movement. Diclofenac reduces the painful phenomena of morning joint constraint and puffiness of soft tissues, and also improves functioning of a musculoskeletal system.
Plasma Cmax of diclofenac at internal reception is observed in 120 minutes. Linkng with serum proteins almost full (99,7%). System clearance at the level of 263 ml/min. Drug can get into synovial fluid. T1/2 is equal to 60-120 minutes. In the form of products of a metabolism of 60% of a dose it is excreted with urine (1% in not changed look), other part is removed with bile. Cumulation of diclofenac is not observed.
Indications to use
Use of Moveks the Asset is shown at the following painful states:
- the musculoskeletal system pathologies which are followed by inflammatory symptomatology, a pain syndrome, degenerative and dystrophic changes vertebral and joint cartilaginous fabrics and also decrease in mobility of joints;
- at various injuries and changes, for the purpose of the fastest forming of a bone callosity;
- periarthritis and osteoarthrites, including pathologies of coxofemoral and knee joints, a spondylarthrosis, intervertebral osteochondrosis;
- at the posttraumatic inflammations of segments of a musculoskeletal system and soft tissues formed because of blows or stretchings;
Use of Moveks of the Asset is completely contraindicated at:
- allergies to mollusks;
- feeding by a breast;
- personal hypersensitivity to drug components;
- peptic ulcer of a gastrointestinal tract (in the acute period);
- perforation or bleeding of a gastrointestinal tract;
- recurrent or acute peptic ulcer of a gastrointestinal tract in the anamnesis;
- perforation or the gastrointestinal bleeding observed in the past at reception of NPVS;
- pathologies of intestines of inflammatory character (ulcer colitis, illness Krone);
- heavy pathologies of kidneys (KK is less than 30 ml/min.) or a liver (including ascites and cirrhosis);
- emergence in the past at reception of NPVS of attacks of bronchial asthma, acute rhinitis, small tortoiseshell, a Quincke's disease;
- tendencies to bleedings;
- congestive heart failure;
- carrying out aortocoronary shunting;
- Ischemic heart disease at patients with a myocardial infarction or stenocardia in the anamnesis;
- pathologies of peripheral arteries;
- cerebrovascular disturbances at patients in whose anamnesis there is mentioning of tranzitorny ischemic attacks or a stroke;
- at children's age.
As a rule, treatment using Moveks the Asset is transferred without any by-effects. Negative effects of therapy are in most cases caused by influence of diclofenac and depend on dosages.
- the phenomena connected with hypersensitivity including itch/rash (violent, erythematic);
- small tortoiseshell;
- multiformny erythema (including Stephens-Johnson's syndrome);
- epidermal toxic necrolysis;
- bronchial asthma (including asthma);
- exfoliative dermatitis (erythrosis);
- Quincke's disease;
- anaphylactoid and anaphylactic manifestations (including hypotension and depressed cases).
Gastrointestinal system and liver:
- abdominal distention;
- abdominal pain;
- feeling of spasms;
- dispepsichesky phenomena;
- changes of a gullet;
- exacerbation of inflammatory pathologies of intestines (ulcer colitis, illness Krone);
- formation of the ulcers of a gastrointestinal tract able to proceed with perforation or bleeding (sometimes with death, in particular at elderly patients);
- emergence of intestinal diafragmopodobny strictures;
- development of bleedings of a gastrointestinal tract (including a melena, a hematemesis, bloody diarrhea);
- colitis or hemorrhagic colitis;
- disturbance of hepatic function;
- fulminant hepatitis;
- increase in level of serumal aminotransferases;
- liver necrosis;
- hepatitis (with jaundice or without that);
- liver failure.
- disturbance of visual function (diplopia, sight illegibility);
- disorders of taste;
- hearing disorder.
- general weakness;
- feeling of alarm;
- sensitivity disturbance;
- psychotic frustration;
- aseptic meningitis;
- increased fatigue;
- confusion of consciousness;
- optic neuritis;
- disturbances of blood circulation of a brain.
- acute insufficiency of kidneys;
- liquid delay;
- papillary necrosis;
- medullary renal necrosis;
- intersticial nephrite;
- tubulointerstitsialny nephrite;
- nephrotic syndrome.
- pains in a breast;
- arterial hypertension;
- heart failure;
- the trombotichesky complications (including a stroke and a myocardial infarction) associated with influence of high doses of diclofenac (150 mg a day) and its prolonged use.
System of a hemopoiesis:
- anemias (including aplastic and hemolitic);
- hair loss;
Moveks Asset, application instruction
Tablets of Moveks the Asset are shown to be accepted preoralno (inside) right after food and only to patients of adult age. As a rule, appoint on the 1st tablet three times at 24 o'clock, washing down 100-200 ml of water.
It is better to limit therapy duration in the recommended dose 3 weeks, but as the medical scheme is selected in an individual order, according to the recommendation of the doctor therapy can continue more than 3 weeks.
Use of Moveks Aktiv9b has to be carried out in the minimum effective dosages throughout the shortest interval of time, according to problems of therapy for each patient separately.
After leveling of a pain syndrome the Comfort is possible transition to administration of drug of Moveks (according to the recommendation of the doctor).
At reception of the overestimated dosages of Moveks of the Asset noted strengthening of side effects, typical for diclofenac.
Unambiguous clinical manifestations of overdose by diclofenac do not exist. In case of reception of its overdoses can be observed: a disorientation, headaches, a ring in ears, nausea/vomiting, drowsiness, pain in epigastriums, dizziness, gastrointestinal bleedings, overexcitation, diarrhea, a faint, a coma, spasms. At intoxication of difficult character forming of symptoms of acute insufficiency of renal function and hepatic defeats is possible.
As a rule, therapy of acute poisonings with drugs of NPVS group including diclofenac, shown arterial hypotonia, spasms, a renal failure, disturbances in a gastrointestinal tract and suppression of breath includes carrying out the symptomatic treatment which is followed by the supporting actions. Carrying out hemoperfusion, hemodialysis and artificial diuresis do not promote the fastest removal of diclofenac from an organism, because of its extensive metabolism and almost full linkng with plasma proteins. At overdose of potentially toxic character recommend to carry out cleaning of a gastrointestinal tract and to appoint sorbents.
Parallel use of diclofenac with Digoxin and drugs of lithium leads to increase of plasma concentration of the last so, during such medicinal combinations it is recommended to control periodically the plasma level of digoxin and lithium.
Because of the increased risk of development of bleedings, careful combinatory appointment with Moveks as the Asset demand antitrombotichesky drugs and anticoagulants.
At reception of diclofenac oppression of tubular renal clearance of the Methotrexate can be observed that leads to increase of its plasma contents and, as a result, to action strengthening. Thereof, it is the best of all to maintain a 24-hour interval of use of NPVS (including diclofenac) and the Methotrexate. In a case when the interval between receptions of these drugs was less than 24 hours, the phenomena of intoxication of difficult character were observed.
Reception of tablets of Moveks the Asset reduces need for drugs of NPVS group.
The combined use of diclofenac with glucocorticoids, and also other NPVS of systemic action increases possibility of expressions and bleedings of a gastrointestinal tract. The diclofenac combination with glucocorticoids can become the reason of more frequent manifestation of side effects. It is necessary to avoid joint purpose of two and more drugs from NPVS group.
In case of purpose of diclofenac along with already accepted anti-hypertensive medicines (APF inhibitors, beta-blockers and so forth) and diuretics observe easing of their hypotensive efficiency, owing to suppression of processes of formation of vazodilatatorny prostaglandins. For this reason it is necessary to appoint this combination of drugs carefully and under a constant control of the ABP, in particular in relation to elderly patients. In need of such association of drugs, patients need to provide adequate hydration. At the same time it is necessary to control functionality of kidneys, because of the increased risk of manifestations of nephrotoxicity of combinatory treatment with APF inhibitors and diuretics.
There are data on increase of risk of development of bleedings at parallel use of diclofenac and anticoagulants in this connection it is recommended to watch attentively the patients who are at the same time accepting this combination of HP and if necessary to modify an anticoagulant dosage. Also it is necessary to watch indicators of coagulability of blood as Moveks the Asset can strengthen effects of anticoagulants. As well as other NPVS, diclofenac in high doses it is capable to suppress platelet aggregation reversibly.
After reception of diclofenac it was reported about forming of both hyper glycemic, and hypoglycemic reactions that demands control over the content of glucose in blood.
Because of impact on prostaglandins of kidneys, drugs of NPVS group can exponentiate nephrotoxicity of Cyclosporine. At the combined use of cyclosporine and Moveks of the Asset it is necessary to lower a hondroprotektor dosage.
Moveks the Asset is capable to influence the serumal content of Warfarin and Cyclosporine.
At co-administration with immunosuppressant takrolimusy its toxic influence on kidneys, by means of suppression of prostaglandins of kidneys increases.
The combined use with antibiotics of a class of hinolon can lead to forming of spasms, irrespective of tracing in the anamnesis of the patient of convulsive attacks or epilepsy. This combination of drugs demands careful use.
Joint reception of diclofenac and Phenytoinum can increase exposure of the last in this connection it is necessary to trace plasma concentration of Phenytoinum.
Parallel use of Colestyraminum and Kolestipol can brake or reduce diclofenac absorption thereof reception of diclofenac is shown at least in 60 minutes prior to, or after 4-6 hours after use of Colestyraminum and Kolestipol.
The concomitant use of NPVS and cardiac glycosides can strengthen symptomatology of heart failure, lower a glomerular filtration rate and increase the plasma maintenance of a glycoside.
Because of presence at drug of diclofenac, Moveks the Asset should not be accepted for 8-12 days after Mifepristone use in view of the fact that this combination can reduce efficiency of Mifepristone.
The careful combined use is demanded by diclofenac and strong CYP2C9 inhibitors (Vorikonazol, Sulfinpyrazonum) as the last, by means of oppression of a metabolism of diclofenac, considerably increase its serumal Cmax.
The medicines which are SIOZS at joint inclusion in NPVS increase risk of forming of bleedings of a gastrointestinal tract.
Parallel therapy with use of kaliysberegayushchy diuretics, Takrolimusa, Cyclosporine or Trimethoprimum can become the reason of increase of serumal level of potassium in this connection at such combination of drugs it is necessary to check the plasma content of potassium constantly.
The conducted clinical trials proved a possibility of the combined use of diclofenac and peroral hypoglycemic HP without disturbance of their clinical performance. However in certain cases observed forming of states hypo — or a hyperglycemia which demanded correction of the dosing mode of antidiabetic drugs.
During therapy of Moveks the Asset recommend to control the plasma level of glucose as a precautionary measure.
Efficiency of treatment of Moveks the Asset increases in a case enrichment of a food allowance vitamins of group A and C, and also salts of magnesium, selenium, copper, manganese and zinc.
Terms of sale
It is possible to buy Moveks the Asset only in the presence of the recipe.
The maximum temperature of storage of drug is equal to 25 °C.
Period of validity
From the date of issue specified on packaging – 3 years.
Independently it is forbidden to exceed the dose of Moveks of the Asset recommended by the doctor.
At reception of some NPVS and the selection TsOG-1/TsOG-2 inhibitors the increased risk of cerebrovascular and cardiovascular trombotichesky complications is observed.
It is necessary to avoid parallel use of Moveks of the Asset and NPVS of systemic action, such as TsOG-2, because of lack of any synergy effect of these drugs, and also the increased possibility of the additive side effects.
With care it is necessary to appoint Moveks of the Asset to the elderly, weakened patients and patients with a lack of weight.
As well as other NPVS, diclofenac, owing to the farmakodinamichesky qualities, it is capable to mask symptomatology of infectious diseases.
The constant control and consultations from medical personnel are demanded by patients in whose anamnesis congestive heart failure and an arterial hypertension as the carried-out treatment with use of NPVS sometimes led to a delay in an organism of liquid and to formation of hypostases is traced.
The patients having heart failure, uncontrollable hypertensia, an ischemic heart disease, occlusion of peripheral arteries, cerebrovascular disturbances, and also patients with cardiovascular risk factors (smoking, a lipidemia, a hypertension, a diabetes mellitus) should appoint the drugs including diclofenac only after a careful assessment of a full clinical picture. In view of the fact that cardiovascular risks of use of NPVS depend on duration of therapy and the used dosages, use of diclofenac needs to be carried out in the smallest effective doses on the shortest span.
At therapy of NPVS bleedings (a melena, a hematemesis), perforation or expression of a gastrointestinal tract which can lead to a lethal outcome were sometimes noted. These manifestations can be observed in any period of carrying out therapy as in the presence, and in the absence of gastrointestinal tract pathologies in the anamnesis or symptoms harbingers. At elderly patients forming of the similar phenomena can lead to more serious complications. In case of suspicions on emergence of expressions or bleedings of a gastrointestinal tract at use of Moveks the Asset it is necessary to suspend treatment and to be convinced of absence or existence of these phenomena.
Because of presence at drug of diclofenac of extra care of use and careful medical supervision patients with symptomatology of disturbances from a gastrointestinal tract demand, and also patients with the suspected perforation, bleeding and an ulcer. The risk of development of the above-stated complications is connected with NPVS dosage, duration of its use and the anamnesis burdened by perforation or bleedings. At elderly patients the increased frequency of negative complications (perforation/bleeding) from a gastrointestinal tract of NPVS associated with reception which can lead to death is traced. Therefore at purpose of therapy it is necessary to consider a question of parallel use of protective medicines (inhibitors of a proton pomp, mizoprostol) and to carry out treatment "under cover" similar drugs.
Patients, in particular advanced age, with the revealed toxicity of a gastrointestinal tract in the anamnesis, need continuous supervision for the purpose of early detection of atypical abdominal symptoms (in particular, bleedings). Careful use is demanded by the patients receiving the accompanying therapy by the drugs increasing risk of developing of bleedings or expressions of a gastrointestinal tract such as: anticoagulants, system glucocorticoids, SIOZS or antiagregant. For decrease in risk of possible toxic influence on a digestive tract, appointment of the smallest the effective initial and supporting dosages is shown to elderly patients.
When diagnosing at patients of pathologies of a liver, purpose of Moveks of the Asset should be carried out with extra care as carrying out therapy by diclofenac can potentially lead to an aggravation of these painful states and increase of level of one or several enzymes of a liver. During long therapy regular control over functionality of a liver is necessary. In case of identification of deviations of indicators of hepatic function from norm which remain at the certain level or tend to development, and also at emergence of clinical symptomatology of diseases of a liver or the other negative phenomena (rash, an eosinophilia) use of Moveks of the Asset needs to be interrupted. Forming of hepatitis can happen without detection of prodromal symptoms. Also careful purpose of diclofenac is demanded by patients with a hepatic porphyria, because of a possible exacerbation of this disease.
There are messages on emergence of serious negative reactions from integuments, up to a lethal outcome, including about Stephens-Johnson's syndrome, exfoliative dermatitis and an epidermal toxic necrolysis observed very seldom and associated with reception of NPVS. The greatest risk of forming of these phenomena is observed in an initiation of treatment, as a rule, in the first month of its carrying out. At the first symptoms of future skin rash, expressions of mucous or other symptoms of hypersensitivity it is necessary to refuse further administration of drug.
Because use of NPVS can cause a delay of liquid and the subsequent formation of hypostases in an organism, care of reception of the drugs containing diclofenac is demanded by patients with disturbance of cordial and renal function, patients with an arterial hypertension in the anamnesis and elderly patients. For the same reason the special attention needs to be paid to patients who pass the accompanying therapy by the diuretics or other drugs capable significantly to influence functionality of kidneys, and also to patients with considerably reduced volume of extracellular liquid which arose for any reason (for example, owing to an extensive surgery). In all above-mentioned cases continuous supervision over function of kidneys is necessary. The treatment termination, as a rule, returns all renal indicators to the parameters observed before its appointment.
At long use of diclofenac recommend to carry out periodically check analyses of maintenance of uniform elements of blood. During treatment of NPVS perhaps reversible oppression of platelet aggregation. Patients with hematologic deviations, hemorrhagic diathesis and disturbances of a hemostasis need the continuous doubled watch.
Patients with asthma, polyps, seasonal rhinitis, HOZL or respiratory persistent infections (in particular in the presence of symptomatology similar to displays of allergic rhinitis), react to treatment using NPVS more often. Observed symptoms of the response to therapy can get a form of the small tortoiseshell, a bronchospasm, a Quincke's disease or to be similar to manifestations of an exacerbation of asthma. In case of these complications acute management can be required. Also it concerns patients with an allergy to other ingredients of drug which can be shown by an itch, rash, urticaria, etc.
For simplification of symptomatology, and also being coordinated with the response to treatment, it is necessary to reconsider requirement of use of diclofenac periodically.
Coincidence on the ATH code of the 4th level:
Analogs of Moveks of the Asset on the main action (hondroprotektorny) are provided by the following drugs:
- Chondroitin Complex;
- Nimesin Plus;
- Artron Triaktiv Forte;
- Osteoartiz Asset (Asset Plus);
- Fleks-A-Min Kompleks;
- Mukosat Neo;
- Moveks Comfort, etc.
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before use of medicine of Moveks the Asset surely consult with the attending physician.